The same platform approach can support fibrosis programs through fibrosis-targeted LNP technologies, as well as oncology and immunology programs through AOC-based approaches targeting immune-related pathways and traditionally undruggable cancer targets.
| Program | Area | Current Focus |
|---|---|---|
| Ampho-100 series | Fibrosis | Fibrosis-targeted LNP programs for MASH/NASH, IPF, CKD, and cardiac fibrosis. |
| Ampho-200 series | Oncology / Immunology | AOC programs for autoimmune or undruggable cancer targets. |
Fibrosis-targeted LNPs deliver RNA payloads to disease-relevant tissues, supporting therapeutic approaches for MASH/NASH, idiopathic pulmonary fibrosis (IPF), chronic kidney disease (CKD), and cardiac fibrosis.
AOC-based approaches are being explored for autoimmune diseases and oncology applications targeting traditionally undruggable cancer targets.
